Strategic Financing to Accelerate FIMECS Protein Degraders Drug Discovery

Kanagawa, Japan, 28, May 2020 - FIMECS, Inc. (“FIMECS”) a private biotechnology company
creating a new class of drugs based on targeted protein degradation, today announced the closing of a550 million JPY (approximately 5.1 million USD) series A financing. The round was co-led by UTokyo
Innovation Platform Co., Ltd. (“UTokyo IPC”) and Kyoto University Innovation Capital (“KyotoiCAP”), with participation from ANRI. The fund raising will enable FIMECS to advance protein
degrader programs against previously thought “undruggable targets”, including preclinical studies ofa lead program that targets IRAK-M protein and further development of FIMECS’s protein degrader
discovery platform, RaPPIDSTM. “We are very excited to initiate the cooperation with Japanese 1st tierinvestors for generating game-changing drugs.” said Yusuke Tominari, Ph.D., Co-Founder, CEO andCSO of FIMECS. “We will accelerate several “undruggable” protein degrader programs including
IRAK-M degrader and development of RaPPIDSTM platform. We believe that proprietary first-in-classdrug discovery programs and the collaboration with partners contribute to deliver life-saving medicines
to patients around the world.”“Targeted protein degradation has huge potential to deliver innovative drugs to the patients sufferingfrom intractable diseases.

It is our delight to work with FIMECS, the leading startup in this field,”

said Katsuhiko Oizumi, President and CEO of UTokyo IPC. “We feel confident that FIMECS will berecognized as a genuine drug discovery biotech with the profound experiences of originating Takeda
Pharmaceuticals and knowledge creation through academic collaborations including the University ofTokyo.”“We are enthusiastic about the significant therapeutic potential of the FIMECS drug discovery
technology based on targeted protein degradation and their strong passion to provide a new option topatients” said Ko Kusumi, President and CEO of Kyoto iCAP. “We look forward to working closelywith the FIMECS team as they collaborate with Kyoto University researchers to develop novel drugcandidates.”“Targeted protein degradation is emerging and exciting modality which can access “undruggabletargets”. By leveraging of FIMECS’s technology and capability in this space, we believe that
innovative drug which can solve unmet medical needs will be delivered to the patients and theirfamilies.” said Anri Samata, General Partner of ANRI. “We are honor to work together with greatentrepreneurs developing advanced technologies and innovative drugs.”

About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for thecurrently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able
to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by
integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will
help providing drugs to the patients all over the world through various internal and collaboration
projects. https://www.fimecs.com/eng/
About IRAK-M program
IRAK-M has an important role in tightly controlling innate immune responsiveness to preserve
homeostasis, mediating immune tolerance, and acts as a negative feedback regulator of TLR/IL-1R
signaling pathway. Targeting IRAK-M, which expression is restricted to myeloid cells, would be
potentially limiting adverse events against non-target tissues. From supporting evidence for the role ofIRAK-M in innate immunosuppressive capacity of tumor-associated macrophages (TAMs) or dendriticcells (DCs), we have developed compounds targeting IRAK-M as an effective cancer-immunotherapy
strategy.
About RaPPIDS™
RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug
discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein
degrader. The platform allows synthesizing and evaluating various degraders quickly based on thecompany’s proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates
with the best combination of target protein binders, linkers, and E3 ligase binders.
###Contact:
FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-32-1169
Email: info@fimecs.com